CDB-4124
Jump to navigation
Jump to search
|
WikiDoc Resources for CDB-4124 |
|
Articles |
|---|
|
Most recent articles on CDB-4124 |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on CDB-4124 at Clinical Trials.gov Clinical Trials on CDB-4124 at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on CDB-4124
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating CDB-4124 Risk calculators and risk factors for CDB-4124
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for CDB-4124 |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
CDB-4124 (Proellex™, Progenta™) is a selective progesterone receptor modulator.[1]
References
- ↑ Attardi BJ, Burgenson J, Hild SA, Reel JR (2004). "In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone". J Steroid Biochem Mol Biol. 88 (3): 277–88. doi:10.1016/j.jsbmb.2003.12.004. PMID 15120421.